

2415F USA

Via Telefax

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended). ~~The A~~ therapeutic method for the treatment of ~~the a~~ mammalian joint with degeneration of the articular cartilage exhibiting degeneration caused by osteoarthritis, ~~characterized by comprising (i) the performance of three applications~~ intraarticular implantation of a pharmaceutically effective dose ~~amount of~~ a viscoelastic composition comprising an aqueous vehicle with 40 ~~compound containing a proportion of 60 mg of chondroitin sulfate and a proportion of 45~~ 30 mg of sodium hyaluronate per cubic centimeter of viscoelastic solution, and/or a proportion of 30 mg of chondroitin sulfate and a proportion of 22.5 mg of sodium hyaluronate per cubic centimeter of said vehicle viscoelastic solution, and/or a proportion of 20 mg of chondroitin sulfate and a proportion of 15 mg of sodium hyaluronate per cubic centimeter of viscoelastic solution, following the standards of intraarticular infiltration, once every 15 days, and ii) the application of a reinforcement or maintenance dose every 3, 6, 9 or 12 months, according to the damage in the articular cartilage of the patient.

2415F USA

Via Telefax

Claim 2 (currently amended). The therapeutic method according to claim 1, wherein in which the mammalian joint is a human joint, the intraarticular implantation is effected with a hypodermic needle, and the articular cartilage can be is selected from the group formed by consisting of the following joints: i) knees, shoulders and sacroiliac; ii) coxofemoral, ankles and elbows; and iii) interphalangeal and wrists.

Give

Claim 3 (currently amended). The therapeutic method according to claim 1, in which each the pharmaceutically effective dose amount is comprises 1.5 cubic centimeters of the compound composition according to claim 1 for the a joint selected from the group consisting of: knee, shoulder or and sacroiliac joints.

Claim 4 (currently amended). The therapeutic method according to claim 1, in which every the pharmaceutically effective dose amount is comprises 0.75 cubic centimeters of the compound composition according to claim 1 for the a joint selected from the group consisting of: coxofemoral, ankle and elbow joints.

Claim 5 (currently amended). The therapeutic method according to claim 1, in which every the pharmaceutically effective dose amount is comprises 0.5 cubic centimeters of the compound according to claim 1 for a joint selected from the group consisting of the interphalangeal and wrist joints.

2415F USA

Via Telefax

Page 25, Paragraph beginning at line 4, please delete in its entirety.